Kiyoshi Ando

机构：Hiroshima University, Tokai University · ORCID：0000-0002-5153-8850

发表论文 542 篇 · 总被引 16112 次 · h-index 59

代表论文

• Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial (2023 · The Lancet Haematology · 被引 73)
• Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1 (2024 · Frontiers in Immunology · 被引 44)
• Clostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation (2024 · Bone Marrow Transplantation · 被引 13)
• R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203 (2023 · British Journal of Haematology · 被引 12)
• Mutations in the SARS-CoV-2 spike proteins affected the ACE2-binding affinity during the development of Omicron pandemic variants (2024 · Biochemical and Biophysical Research Communications · 被引 10)
• Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study (2024 · International Journal of Hematology · 被引 8)